Lars hman - Lipigon Pharmaceuticals Bus Chairman
| LPGO Stock | SEK 0.17 0.01 6.25% |
Insider
Lars hman is Bus Chairman of Lipigon Pharmaceuticals AB
| Age | 66 |
| Phone | 46 7 05 78 17 68 |
| Web | https://www.lipigon.se |
Lipigon Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.9394) % which means that it has lost $0.9394 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.7019) %, meaning that it generated substantial loss on money invested by shareholders. Lipigon Pharmaceuticals' management efficiency ratios could be used to measure how well Lipigon Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pr MD | Oncopeptides AB | N/A | |
| Emanuel Bjrne | Hansa Biopharma AB | 50 | |
| MSc MD | Oncopeptides AB | N/A | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| Sren MSc | Hansa Biopharma AB | 58 | |
| Jorgen Drejer | Saniona AB | 68 | |
| Rami Levin | Saniona AB | 54 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Palle MS | Saniona AB | 65 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Karin Nielsen | Saniona AB | N/A | |
| Anita BCom | Saniona AB | 55 | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| MSc MSc | Oncopeptides AB | 53 | |
| Janus Larsen | Saniona AB | 51 | |
| Annika MBA | Oncopeptides AB | 57 | |
| MBA MSc | Saniona AB | 63 | |
Management Performance
| Return On Equity | -1.7 | |||
| Return On Asset | -0.94 |
Lipigon Pharmaceuticals Leadership Team
Elected by the shareholders, the Lipigon Pharmaceuticals' board of directors comprises two types of representatives: Lipigon Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipigon. The board's role is to monitor Lipigon Pharmaceuticals' management team and ensure that shareholders' interests are well served. Lipigon Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipigon Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lars hman, Bus Chairman | ||
| Stefan Nilsson, CoFounder CEO | ||
| Michael Owens, Chief Officer | ||
| Pr Olivecrona, Cofounder Member |
Lipigon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipigon Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.7 | |||
| Return On Asset | -0.94 | |||
| Operating Margin | (338.33) % | |||
| Current Valuation | 5.58 M | |||
| Shares Outstanding | 20.24 M | |||
| Shares Owned By Insiders | 38.47 % | |||
| Shares Owned By Institutions | 12.51 % | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 147.83 X | |||
| Revenue | 3.18 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lipigon Stock Analysis
When running Lipigon Pharmaceuticals' price analysis, check to measure Lipigon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipigon Pharmaceuticals is operating at the current time. Most of Lipigon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lipigon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipigon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lipigon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.